lyophilization comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-07-05. Where a claim depends on a specific study, the study is described rather than over-claimed.
The main chemical liabilities of this sequence are peptide-bond hydrolysis and possible aspartate-related reactions, since the peptide contains aspartic acid residues but no cysteine, methionine, or tryptophan. Absence of those three residues removes the most common oxidation and disulfide pathways from consideration. Studies of related peptides indicate that aspartate isomerisation and aspartimide formation occur most readily at Asp-Gly and Asp-Ala positions, and open questions remain about how quickly those reactions proceed under ordinary laboratory conditions. Storage guidance typically emphasises cool, dry, dark conditions to slow hydrolysis.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography, often paired with mass spectrometry using electrospray or MALDI ionisation. Amino acid analysis and peptide mapping by enzymatic digestion provide additional sequence-level confirmation. Purity is commonly reported as an area percentage from a chromatographic trace, and water content can be measured by Karl Fischer titration. Reported masses may differ by tens of daltons between sources because preparations can contain acetate or trifluoroacetate counterions, and such differences are not by themselves evidence of a different peptide.
Handling practice centers on limiting moisture, heat, and mechanical stress. Powder is typically allowed to reach room temperature before opening so that condensation does not form on the contents, and solutions are prepared with sterile or low-particulate water. Peptides can adsorb to certain plastics and membrane filters, so container and filter material is sometimes specified to reduce losses at low concentrations. Working aliquots are usually frozen separately rather than sampled repeatedly from one stock. Recording lot number, preparation date, and storage conditions supports later comparison between experiments.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography, which separates the target peptide from truncated sequences and other synthesis by-products. Mass spectrometry, typically electrospray ionization coupled to liquid chromatography, confirms the expected mass and helps detect modifications. Amino acid analysis can verify composition when residue-level confirmation is needed. Because common impurities differ from the target by only one or two residues, chromatographic resolution often matters more than a single headline purity percentage. Impurity profiles are most informative when compared against a validated reference standard.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilised material; shade varies slightly between lots |
| Solubility in water | Freely soluble | Dissolves in water, saline, and aqueous buffers |
| Solubility in nonpolar solvents | Poorly soluble | Not compatible with oils or hydrocarbon solvents |
| Typical storage temperature | About −20 °C | Lyophilised, dry, dark storage slows hydrolysis |
| Common purity method | Reversed-phase HPLC | Area percentage, usually paired with mass spectrometry |
Most published findings come from rodent models, where the peptide has been examined in wound-healing, gastrointestinal-lesion, tendon, and vascular-injury preparations. A smaller number of early human studies have been reported, chiefly in inflammatory bowel conditions, but the public record is short and has not led to marketing approval in the United States or the European Union. Reviewers therefore classify the compound as investigational, and whether animal results carry over to people remains an open question rather than a settled one.
Outside laboratory supply channels, the peptide is sold as a research chemical, a category that carries no requirement to demonstrate purity, identity, or freedom from contamination. Because it is not an approved medicine, products labeled BPC-157 sit in a regulatory gap in many countries, and actual content may differ from the label. Sports organizations list it among prohibited substances, so its presence in an athlete's sample can produce a doping finding regardless of how the material was obtained.
Within the research literature, the peptide is discussed through several provisional mechanisms, including cytoprotection, modulation of growth factor signaling, and interaction with the nitric oxide system. None of these mechanisms is fully characterized, and no single pathway is universally accepted. Review articles typically note the gap between consistent animal findings and sparse human evidence. The compound is classified as a research chemical rather than an approved pharmaceutical, which shapes how studies are designed, funded, and reported.
BPC-157 is a synthetic pentadecapeptide with the sequence GEPPPGKPADDAGLV, corresponding to a partial fragment of a larger protein detected in human gastric juice. The name derives from the parent protein designation BPC, an abbreviation of body protection compound, with 157 acting as a fraction or batch identifier used by the original investigators. Its molecular weight is approximately 1419 daltons, and the chain contains no unusual residues or disulfide bridges. In the literature it is described as a short, water-soluble fragment rather than a complete natural protein.
Long-term storage of the dry powder is typically described at minus twenty degrees Celsius or colder, while shorter holding periods may use ordinary refrigeration. Repeated warming and cooling cycles are discouraged because they stress the material and can promote aggregation or loss. Light exposure and residual moisture are both treated as avoidable sources of degradation, and working aliquots are often prepared to limit how many times a container is opened. Sealed vials with a desiccant are the usual container.
Quality assessment rests on two separate questions: whether the chain is the intended one, and how much of the sample is that chain. Reverse-phase high-performance liquid chromatography with ultraviolet detection is the standard purity measurement, while mass spectrometry confirms identity through the observed molecular mass. Amino acid analysis and sequence verification provide further checks. A reported purity percentage describes the proportion of the sample represented by the main peak, not the amount of peptide by mass, since counter-ions and water make up part of any lyophilized lot.
== History == Medtronic replaced the Paradigm insulin pump with its new pump platform, the 640G, internationally in 2015. Its successive pumps have used the same form factor. In the United States, the 670G was released in 2017. It used an algorithm called SmartGuard to adjust the basal insulin rate based on readings from the CGM (continuous glucose monitor). A more advanced SmartGuard algorithm was released in 2020 (2023 in the United States) as part of the 780G. It can deliver automated boluses and has an optional glucose target of 100 mg/dl. The 670G used Medtronic's own proprietary algorithm. For the 780G, the SmartGuard algorithm was adapted from an algorithm licensed by Medtronic in 2015 from medical technology company DreaMed. DreaMed, based at the Schneider Children's Medical Center of Israel in Tel Aviv, created the algorithm in the late 2000s. At first called MD-Logic Artificial Pancreas, then GlucoSitter, it used machine learning to increase the patient's time in the 80–120 mg/dl range. DreaMed's algorithm performed well in clinical trials as of 2011. Initially, the pump was compatible only with MiniMed's own CGMs, the Guardian 3 and Guardian 4. In 2025, MiniMed introduced two new CGMs for the 780G, the Simplera Sync and the Instinct, made by Abbott Laboratories.
Authentic extracts elevated to the rank of originals (Series A); Declarations by individuals (Series B); Official reconstructions based on documents held by the administration or registers transferred to it (Series C). This operation lasted until 1897 and ended due to a lack of funds. It made it possible to restore slightly more than 2.6 million records, most of which date from the 19th century. Only 347,000 records were restored for the Ancien Régime, with just five dating back to the 16th century. Altogether, the restored documents represent only one-third of those that were destroyed. Birth records are the most numerous, with approximately 1,422,000 records dating from 1550 to 1859, compared to around 922,000 death records from 1568 to 1859 and 322,000 marriage records from 1630 to 1859. However, the vast majority of data, particularly that concerning families without descendants, is lost forever. The reconstructed records are preserved at the Archives of Paris. Their duplicates, stored at the Montlignon Fort (Val-d’Oise), were destroyed in a fire in June 1974.
While in the healthy heart, waves of electrical impulses originate in the sinus node before spreading to the rest of the atria, the atrioventricular node, and finally the ventricles (referred to as a normal sinus rhythm), this normal rhythm can be disrupted. Abnormal heart rhythms or arrhythmias may be asymptomatic or may cause palpitations, blackouts, or breathlessness. Some types of arrhythmia such as atrial fibrillation increase the long term risk of stroke. Some arrhythmias cause the heart to beat abnormally slowly, referred to as a bradycardia or bradyarrhythmia. This may be caused by an abnormally slow sinus node or damage within the cardiac conduction system (heart block). In other arrhythmias the heart may beat abnormally rapidly, referred to as a tachycardia or tachyarrhythmia. These arrhythmias can take many forms and can originate from different structures within the heart—some arise from the atria (e.g. atrial flutter), some from the atrioventricular node (e.g. AV nodal re-entrant tachycardia) whilst others arise from the ventricles (e.g. ventricular tachycardia). Some tachyarrhythmias are caused by scarring within the heart (e.g. some forms of ventricular tachycardia), others by an irritable focus (e.g. focal atrial tachycardia), while others are caused by additional abnormal conduction tissue that has been present since birth (e.g. Wolff-Parkinson-White syndrome). The most dangerous form of heart racing is ventricular fibrillation, in which the ventricles quiver rather than contract, and which if untreated is rapidly fatal.
The enzyme phenylalanine hydroxylase normally converts the amino acid phenylalanine into the amino acid tyrosine. If this reaction does not occur, phenylalanine accumulates and tyrosine is deficient. Excessive phenylalanine can be metabolized into phenylketones through the minor route, a transaminase pathway with glutamate. Metabolites include phenylacetate, phenylpyruvate and phenethylamine. Elevated levels of phenylalanine in the blood and detection of phenylketones in the urine is diagnostic, however, most patients are diagnosed via newborn screening.
Before receiving his permanent prison assignment, Noriega was placed in the Federal Detention Center, Miami. Noriega was incarcerated in the Federal Correctional Institution, Miami. Under Article 85 of the Third Geneva Convention, Noriega was considered a prisoner of war, despite his conviction for acts committed prior to his capture by the "detaining power" (the U.S.). This status meant that he had his own prison cell, furnished with electronics and exercise equipment. His cell was nicknamed "the presidential suite". While Noriega was in prison, he was visited regularly over two years by two evangelical Christian ministers, Clift Brannon and Rudy Hernandez. Noriega, nominally a Roman Catholic, was reported to have undergone a conversion to evangelical Christianity in May 1990, and was baptized in October 1992, while still in prison. Noriega's prison sentence was reduced from 40 to 30 years by the judge, then to 17 years for good behavior. His U.S. sentence thus ended on September 9, 2007, though his incarceration ended up being extended while extradition requests by other countries were being adjudicated.
Sources: en.wikipedia.org
Dietary supplements containing ephedra alkaloids are unsafe, with reports of serious side effects and ephedra-related deaths. In response to accumulating evidence of adverse effects and deaths related to ephedra, the U.S. Food and Drug Administration (FDA) banned the sale of supplements containing ephedrine alkaloids in 2004. The ban was challenged in court by ephedra manufacturers, but ultimately upheld in 2006 by the U.S. Court of Appeals for the Tenth Circuit. Ephedra extracts not containing ephedrine have not been banned by the FDA and are still sold legally.
C-value The total amount of DNA contained within a haploid nucleus (e.g. a gamete) of a particular organism or species, expressed in number of base pairs or in units of mass (typically picograms); or, equivalently, one-half the amount in a diploid somatic cell. For simple diploid eukaryotes the term is often used interchangeably with genome size, but in certain cases, e.g. in hybrid polyploids descended from parents of different species, the C-value may actually represent two or more distinct genomes contained within the same nucleus. C-values apply only to genomic DNA, and notably exclude extranuclear DNA.
Like many other antifungals and antibiotics, nystatin has bacterial origin. It was isolated from Streptomyces noursei in 1950 by Elizabeth Lee Hazen and Rachel Fuller Brown, who were doing research for the Division of Laboratories and Research of the New York State Department of Health. Hazen found a promising micro-organism in the soil of a friend's dairy farm. She named it Streptomyces noursei, after Jessie Nourse, the wife of the farm's owner. Hazen and Brown named nystatin after the New York State Health Department in 1954. The two discoverers patented the drug, and then donated the $13 million in profits to a foundation to fund similar research.
Research indicates that systematic physical stimuli from standard electronic devices, such as tablets with headphones, may treat injured nervous systems online by modulating neuronal plasticity. Evidence suggests that teleneurotherapy could enhance neurological treatment if it incorporates the therapeutic effect of a systematic abiotic impact of physical forces with key parameters of mother-fetus interaction. Recent research has shown therapeutic effects when implementing the APIN method in the online treatment of patients with various neurological conditions. Telenutrition refers to the use of video conferencing or telephony to provide online consultations by nutritionists or dieticians. Telerehabilitation (or e-rehabilitation) is the delivery of rehabilitation services over telecommunication networks and the Internet. Most services fall into two categories: clinical assessment (evaluating the patient's functional abilities in their environment) and clinical therapy.
Sources: en.wikipedia.org
=== Modern era (20th and 21st centuries) === As time progresses and technology advances, there is a constant need for change in the approach researchers take in their studies. Tissue engineering has continued to evolve over centuries. Tissue engineers have the ability to remake many of the tissues in the body through the use of modern techniques such as microfabrication and three-dimensional bioprinting in conjunction with native tissue cells/stem cells. These advances have allowed researchers to generate new tissues in a much more efficient manner. For example, these techniques allow for more personalization which allow for better biocompatibility, decreased immune response, cellular integration, and longevity. There is no doubt that these techniques will continue to evolve, as we have continued to see microfabrication and bioprinting evolve over the past decade. In 1960, Wichterle and Lim were the first to publish experiments on hydrogels for biomedical applications by using them in contact lens construction. Work on the field developed slowly over the next two decades, but later found traction when hydrogels were repurposed for drug delivery. In 1984, Charles Hull developed bioprinting by converting a Hewlett-Packard inkjet printer into a device capable of depositing cells in 2D. Three dimensional printing (3D printing) is a type of additive manufacturing which has since found various applications in medical engineering, due to its high precision and efficiency.
=== Laws === There are no laws as such in the Culture. Social norms are enforced by convention (personal reputation, "good manners", and by, as described in The Player of Games, possible ostracism and involuntary supervision for more serious crimes). Minds generally refrain from using their all-seeing capabilities to influence people's reputations, though they are not necessarily themselves above judging people based on such observations, as described in Excession. Minds also judge each other, with one of the more relevant criteria being the quality of their treatment of sentients in their care. Hub Minds for example are generally nominated from well-regarded GSV (the largest class of ships) Minds, and then upgraded to care for the billions living on the artificial habitats. Serious prohibitions exist against harming sentient beings, or forcing them into undertaking any act (another concept that seems unnatural to and is, in fact, almost unheard of by almost all Culture citizens). As mentioned in The Player of Games, the Culture does have the occasional "crime of passion" (as described by an Azadian) and the punishment was to be "slap-droned", or to have a drone assigned to follow the offender and "make sure [they] don't do it again". While the enforcement in theory could lead to a Big Brother-style surveillance society, in practice social convention among the Minds prohibits them from watching, or interfering in, citizens' lives unless requested, or unless they perceive severe risk.
== Recognition and awards == In 2007, Armstrong was honored with the inaugural Georgetown Distinguished Award for Diabetic Limb Salvage. In 2008, he was the 25th and youngest-ever member elected to the Podiatric Medicine Hall of Fame. In 2010, he was the youngest ever recipient of the Roger Pecoraro Award and Lectureship from the American Diabetes Association. That same year, he was also named the 2010 Honorary Fellow of the American College of Certified Wound Specialists as well as the inaugural recipient of the William S. Baer Award for Advances in Biosurgery/Biotherapy by the BioTherapeutics, Education & Research (BTER) Foundation. He was the first podiatric surgeon to become a member of the Society for Vascular Surgery and the first American podiatric surgeon to be named fellow of the Royal College of Physicians and Surgeons, Glasgow. Armstrong is past Chair of Scientific Sessions for the ADA's Foot Care Council, and a past member of the National Board of Directors of the American Diabetes Association. He sits on the Infectious Diseases Society of America's Diabetic Foot Infection Advisory Committee. In 2011, he was appointed Chair of the World Diabetic Foot Commission of the FIP, representing clinicians from more than 30 nations.
It has also been posited that in the region beyond A > 300, an entire "continent of stability" consisting of a hypothetical phase of stable quark matter, comprising freely flowing up and down quarks rather than quarks bound into protons and neutrons, may exist. Such a form of matter is theorized to be a ground state of baryonic matter with a greater binding energy per baryon than nuclear matter, favoring the decay of nuclear matter beyond this mass threshold into quark matter. If this state of matter exists, it could possibly be synthesized in the same fusion reactions leading to normal superheavy nuclei, and would be stabilized against fission as a consequence of its stronger binding that is enough to overcome Coulomb repulsion.
== History == Chemical equilibria in marine and freshwater systems were calculated according to various conventions for most of the 20th century, which led to discrepancies among laboratories' calculations and limited scientific reproducibility. CO2SYS was first published by Ernie Lewis and Doug Wallace in 1998 as a DOS-interface program written in QBasic. Subsequent developments have included several MATLAB implementations, two Microsoft Excel templates, a Python package "PyCO2SYS", and an R package inspired by CO2SYS, "seacarb". Development of the various CO2SYS programs continues as of 2021 with the addition of more chemical equilibrium parameters and compatibility with a wider range of environments, e.g. anoxic waters.
Sources: en.wikipedia.org
Lyophilised peptide powders are generally kept frozen or refrigerated, dry, and protected from light. Sealed vials limit moisture uptake and slow hydrolysis. Such guidance comes from general peptide chemistry rather than from stability studies specific to every product.
Reversed-phase HPLC is the standard approach, with purity expressed as a percentage of total peak area. Mass spectrometry confirms the expected molecular mass and can reveal adducts or truncated sequences. Neither method on its own establishes biological activity.
Small mass differences often reflect different counterions, such as acetate versus trifluoroacetate, or bound water rather than a different amino acid sequence. Mass spectrometry can distinguish these forms when the ionisation conditions are known. Exact sequence confirmation requires peptide mapping or tandem mass spectrometry.
Reversed-phase liquid chromatography with ultraviolet detection gives a purity estimate, while mass spectrometry confirms molecular mass and flags modifications. Amino acid analysis can add compositional confirmation. Results are most meaningful when a validated reference standard is run alongside the sample.